Basic Details
| Item | Value |
|---|---|
| Title | Long Basilea Pharmaceutica (SIX: BSLN / OTC: BPMUF) on Raised Guidance and Fosmanogepix Phase-3 Catalyst |
| Type | Trading |
| Difficulty | 30 |
| Ideal Capital | 10000 |
| ROI | 29% |
| ETA on ROI | 9 |
| Target Audience | Retail and semi-professional equity investors with access to the SIX Swiss Exchange or US OTC markets |
| Target Countries | Switzerland, Germany, EU, UK, USA |
| Target Demographics | Adults 25-65, male and female, risk-tolerant investors interested in biotech/pharma, STEM or finance backgrounds, who follow clinical-trial catalysts |
| Description | Open a long position in Basilea Pharmaceutica after the raised FY2026 guidance. The company is profitable, growing revenue 14% to CHF 119M in H1, with operating profit +32% and net profit +77%. The Fosmanogepix Phase-3 program (first-in-class Gwt1 antifungal for invasive candidiasis/candidemia) is on track and is a major catalyst. Entry strategy: buy on a post-news pullback/consolidation near CHF 62.00. Take profit at CHF 80.00 (+29%) within 9-12 months as Phase-3 data readouts and continued Cresemba/Zevtera royalty growth re-rate the stock. Hard stop-loss at CHF 53.00 (-15%), giving approximately a 2:1 reward-to-risk ratio. Position size 5-10% of portfolio. Execute through a Swiss/EU broker with SIX access (e.g., Swissquote, IBKR) or US OTC ticker BPMUF. Reassess if Fosmanogepix Phase-3 misses its primary endpoint or if guidance is cut. |
| Monetization | Capital appreciation from share price increase; proceeds can be reinvested. No meaningful dividend expected as the company reinvests in its pipeline. |
| Pros |
|
| Cons |
|
